We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-21.79%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.63B
AUM Growth
-$1.11B
(-30%)
Cap. Flow
-$114M
Cap. Flow
% of AUM
-4.34%
Top 10 Holdings %
Top 10 Hldgs %
51.48%
Holding
146
New
29
Increased
20
Reduced
29
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solid Biosciences
SLDB
|
+$123M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$77.8M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$47.7M |
| 4 |
Allogene Therapeutics
ALLO
|
+$41M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$72M |
| 2 |
CORI
Corium International, Inc.
CORI
|
+$60.5M |
| 3 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$43.4M |
| 4 |
Intuitive Surgical
ISRG
|
+$41.6M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$37.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.02% |
| 2 | Financials | 0.08% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$18.3B
| $315M | 12% |
4,608,554
-168,700
| -4% | -$16.2M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $223M | 8.48% |
5,425,726
+276,816
| +5% | +$10.4M |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $192M | 7.3% |
20,724,424
+30,000
| +0.1% | +$330K |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $138M | 5.26% |
3,790,216
-17,416
| -0.5% | -$713K |
|
|
5
Iovance Biotherapeutics
IOVA
$2.04B
| $108M | 4.12% |
12,241,111
+4,950,912
| +68% | +$47.7M |
|
|
6
Solid Biosciences
SLDB
$794M
| $105M | 4.01% |
+261,815
| New | +$123M |
|
7
Crinetics Pharmaceuticals
CRNX
$8.88B
| $77.6M | 2.95% |
2,587,953
| – | – |
|
|
QTNT
8
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $66M | 2.51% |
269,726
+50,000
| +23% | +$13.1M |
|
|
AMRN
9
Amarin Corp
AMRN
$298M
| $64.6M | 2.46% |
243,780
+213,270
| +699% | +$77.8M |
|
10
Ascendis Pharma A/S
ASND
$16.8B
| $63M | 2.4% |
1,052,647
-20,000
| -2% | -$1.26M |
|
|
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $55.6M | 2.12% |
1,430,171
+63,193
| +5% | +$2.48M |
|
12
argenx
ARGX
$55.4B
| $53.9M | 2.05% |
560,941
| – | – |
|
|
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $53.5M | 2.04% |
1,075,216
-13,953
| -1% | -$768K |
|
14
Merit Medical Systems
MMSI
$4.74B
| $52.2M | 1.99% |
949,198
-45,000
| -5% | -$2.68M |
|
15
Travere Therapeutics
TVTX
$5.14B
| $49.8M | 1.89% |
3,342,038
+129,167
| +4% | +$3.21M |
|
16
MeiraGTx Holdings
MGTX
$1.08B
| $45.3M | 1.73% |
4,703,398
| – | – |
|
17
CytomX Therapeutics
CTMX
$694M
| $43.6M | 1.66% |
2,911,715
+250,000
| +9% | +$3.71M |
|
|
BPMC
18
DELISTED
Blueprint Medicines
BPMC
| $43.5M | 1.65% |
857,326
-83,821
| -9% | -$5.09M |
|
|
19
Allogene Therapeutics
ALLO
$583M
| $41.6M | 1.58% |
+1,543,790
| New | +$41M |
|
|
LJPC
20
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $41M | 1.56% |
4,313,611
| – | – |
|
|
XLRN
21
DELISTED
Acceleron Pharma
XLRN
| $39.9M | 1.52% |
905,017
-623,188
| -41% | -$31.1M |
|
|
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
| $39.5M | 1.5% |
1,704,330
| – | – |
|
|
VBIV
23
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $38.3M | 1.46% |
798,385
+476,190
| +148% | +$26.1M |
|
|
ATNX
24
DELISTED
Athenex, Inc. Common Stock
ATNX
| $32.5M | 1.24% |
254,801
+111,325
| +78% | +$28.3M |
|
|
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $31.1M | 1.18% |
2,825,000
+2,800,511
| +11,436% | +$39M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2018 Portfolio in Review
As of Q4 2018, Perceptive Advisors held 146 positions worth $2.63B, down 30% from $3.74B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $114M in Q4 2018, closing 45 positions and reducing 29 holdings. Its most notable exit was Corium International, Inc., an estimated $60.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Perceptive Advisors opened a new position in Solid Biosciences worth $105M.
- Perceptive Advisors's largest Q4 2018 buy was Solid Biosciences: 261,815 shares worth $105M.
- Perceptive Advisors added most to Amarin Corp in Q4 2018, an estimated $77.8M increase.
- Perceptive Advisors's biggest Q4 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $72M.
- Perceptive Advisors fully exited Corium International, Inc. in Q4 2018, selling an estimated $60.5M.
- Perceptive Advisors's ten largest holdings make up 51% of its $2.63B portfolio in Q4 2018.
- Perceptive Advisors opened 29 new positions and closed 45 in Q4 2018.
- Perceptive Advisors's portfolio value fell 30% quarter-over-quarter to $2.63B.
Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.